Congratulations to Dr. Robert Springer and the entire team at DelRicht Research at Springer Wellness and Restorative Health in Atlanta, GA, for screening the first patient study-wide in an ongoing Phase 2 Avian Flu Vaccine Trial.

This early milestone is a reflection of DelRicht Research’s operational readiness and dedication to rapid study startup. Each participating site moved quickly to screen their first patients within hours of activation, but it was the Atlanta team that led the charge, setting the pace for the entire trial.

Dr. Robert Springer’s site has consistently demonstrated swift, efficient execution, and this achievement highlights not only their commitment to advancing public health but also the strength of DelRicht’s streamlined processes across our research network.

We’re proud to support investigators like Dr. Springer and to see this level of momentum in such a critical study, and grateful to all sites for their continued efforts in bringing vaccine innovation to patients faster.

Learn more about DelRicht Research and our growing infectious disease portfolio at www.delrichtresearch.com.